Skip to main content
Evidence Snapshot

R2

CHEMBL614385 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614385
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats R2 as ChEMBL target CHEMBL614385. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
R2
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614385
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why R2 matters

As of 2026-09-13

R2 is reviewed as R2; the current evidence base includes 6 approved drugs, 63 compounds, and 32 assays, with lead potency reaching pChEMBL 8.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 6 approved drugs, 63 compounds, and 32 assays for this target. The dominant activity type is IC50. CHEMBL1834488 is the current potency anchor at pChEMBL 8.8.

Use CHEMBL1834488 as the tractability anchor when discussing potency (pChEMBL 8.8).

Activity source · ChEMBL 36 via Core Engine
6 approved pChEMBL 8.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why R2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

63
Total Compounds
32
Total Assays
6
Approved Drugs
IC50: 153.0, EC50: 6.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1834488
 8.8 IC50 —
No preferred name
CHEMBL225072
 8.3 IC50 Approved
No preferred name
CHEMBL119
 8.2 IC50 Approved
No preferred name
CHEMBL192632
 7.6 IC50 —
No preferred name
CHEMBL590740
 7.6 IC50 —

Approved Drugs

Structure Compound First Approval
PRALATREXATE
CHEMBL1201746
 2009
PEMETREXED
CHEMBL225072
 2004
RALTITREXED
CHEMBL225071
 1996
TRIMETREXATE
CHEMBL119
 1993
METHOTREXATE
CHEMBL34259
 1953
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:56Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614385